Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

NCT04703920 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Metastatic Castration-resistant Prostate Cancer
Metastatic Ovarian Carcinoma
Metastic or Unresectable Pancreatic Adenocarcinoma

Interventions

DRUG: Talazoparib
DRUG: Belinostat

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]
[object Object]